Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David K Packham

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Nephrology (Carlton, Vic.)|September 7, 2007
Thin basement membrane nephropathy and IgA glomerulonephritis: can they be distinguished without renal biopsy?David K Packham
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|July 10, 2015
Potential New Agents for the Management of HyperkalemiaDavid K Packham, Mikhail Kosiborod
Expert Opinion on Drug Metabolism & Toxicology|March 22, 2016
Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemiaDavid K Packham, Mikhail Kosiborod
The New England Journal of Medicine|April 18, 2015
New agents for hyperkalemiaDavid K Packham, Henrik S Rasmussen, Bhupinder Singh
The New England Journal of Medicine|April 16, 2015
Sodium zirconium cyclosilicate for urgent therapy of severe hyperkalemiaMikhail Kosiborod, W Frank Peacock, David K Packham
Seminars in Nephrology|May 10, 2005
Hematuria in thin basement membrane nephropathyDavid K Packham, Vlado Perkovic, Judy Savige, et al.
Ebiomedicine|October 17, 2016
Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation StudyDavid K Packham, Ian R Fraser, Peter G Kerr, et al.
American Journal of Nephrology|October 29, 2019
Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZESimon D Roger, Bruce S Spinowitz, Edgar V Lerma, et al.
Nephrology (Carlton, Vic.)|March 20, 2013
Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockersSara E Ivory, David K Packham, Anne T Reutens, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 27, 2020
Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trialsSimon D Roger, Bruce S Spinowitz, Edgar V Lerma, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Nephrology (Carlton, Vic.)|September 7, 2007
Thin basement membrane nephropathy and IgA glomerulonephritis: can they be distinguished without renal biopsy?David K Packham
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|July 10, 2015
Potential New Agents for the Management of HyperkalemiaDavid K Packham, Mikhail Kosiborod
Expert Opinion on Drug Metabolism & Toxicology|March 22, 2016
Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemiaDavid K Packham, Mikhail Kosiborod
The New England Journal of Medicine|April 18, 2015
New agents for hyperkalemiaDavid K Packham, Henrik S Rasmussen, Bhupinder Singh
The New England Journal of Medicine|April 16, 2015
Sodium zirconium cyclosilicate for urgent therapy of severe hyperkalemiaMikhail Kosiborod, W Frank Peacock, David K Packham
Seminars in Nephrology|May 10, 2005
Hematuria in thin basement membrane nephropathyDavid K Packham, Vlado Perkovic, Judy Savige, et al.
Ebiomedicine|October 17, 2016
Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation StudyDavid K Packham, Ian R Fraser, Peter G Kerr, et al.
American Journal of Nephrology|October 29, 2019
Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZESimon D Roger, Bruce S Spinowitz, Edgar V Lerma, et al.
Nephrology (Carlton, Vic.)|March 20, 2013
Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockersSara E Ivory, David K Packham, Anne T Reutens, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 27, 2020
Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trialsSimon D Roger, Bruce S Spinowitz, Edgar V Lerma, et al.
Pageof 2